RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.53B
AUM Growth
+$116M
Cap. Flow
-$73.8M
Cap. Flow %
-2.09%
Top 10 Hldgs %
47.92%
Holding
99
New
17
Increased
28
Reduced
21
Closed
18
Avg Time Held Equity + Options
1.4 years
Top 10 Avg Time Held Equity + Options
1.3 years
Top 20 Avg Time Held Equity + Options
1.4 years
Avg Time Held Equity only
1.4 years
Top 10 Avg Time Held Equity only
1.3 years
Top 20 Avg Time Held Equity only
1.4 years

Top Buys

Rank Stock Value
1
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$50.1M
3
FOLD icon
Amicus Therapeutics
FOLD
+$40.3M
4
CNC icon
Centene
CNC
+$37.3M
5
STOK icon
Stoke Therapeutics
STOK
+$27.4M

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$82.5M
2
ARRY icon
Array Biopharma Inc
ARRY
+$62.3M
3
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$49.3M
4
PEN icon
Penumbra
PEN
+$47.5M
5
XNCR icon
Xencor
XNCR
+$46.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.51%
2 Miscellaneous 2.32%
3 Financials 2.17%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$405M 11.47%
8,752,254
-2,218,264
-20% -$62.3M
2013 Q2
24 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$284M 8.05%
22,792,634
+3,176,572
+16% +$40.3M
2013 Q2
24 quarters
FATE icon
3
Fate Therapeutics
FATE
$230M
$210M 5.95%
10,359,666
– –
2015 Q2
16 quarters
ARGX icon
4
argenx
ARGX
$51.9B
$151M 4.28%
1,068,832
+49,771
+5% +$6.32M
2017 Q4
6 quarters
QURE icon
5
uniQure
QURE
$1.43B
$130M 3.69%
1,669,525
+362,003
+28% +$23.1M
2018 Q2
4 quarters
BOLD icon
6
DELISTED
Audentes Therapeutics, Inc
BOLD
$113M 3.18%
2,972,167
+236,900
+9% +$9.1M
2016 Q3
11 quarters
EPZM
7
DELISTED
Epizyme, Inc
EPZM
$110M 3.1%
8,729,142
+1,035,122
+13% +$13.3M
2017 Q3
7 quarters
ALLK icon
8
DELISTED
Allakos
ALLK
$99.7M 2.82%
2,300,301
+465,891
+25% +$19.1M
2018 Q3
3 quarters
ALDR
9
DELISTED
Alder Biopharmaceuticals
ALDR
$97M 2.75%
8,244,896
– –
2016 Q3
11 quarters
ATRA icon
10
Atara Biotherapeutics
ATRA
$95.4M
$92.5M 2.62%
184,037
+4,620
+3% +$3.26M
2014 Q4
18 quarters
TCDA
11
DELISTED
Tricida, Inc. Common Stock
TCDA
$76.8M 2.17%
1,945,200
+1,454,900
+297% +$51.2M
2018 Q2
4 quarters
EHTH icon
12
eHealth
EHTH
$19.1M
$76.5M 2.17%
888,705
-333,700
-27% -$22.5M
2016 Q4
10 quarters
BMY icon
13
Bristol-Myers Squibb
BMY
$120B
$75.7M 2.14%
1,669,400
+69,700
+4% +$3.25M
2018 Q4
2 quarters
TNDM icon
14
Tandem Diabetes Care
TNDM
$1.12B
$75.2M 2.13%
1,166,032
+310,100
+36% +$20M
2018 Q3
3 quarters
RGNX icon
15
Regenxbio
RGNX
$458M
$71.5M 2.02%
1,391,376
-28,966
-2% -$1.45M
2017 Q1
9 quarters
WVE icon
16
Wave Life Sciences
WVE
$617M
$71M 2.01%
2,719,707
-111,800
-4% -$3.14M
2015 Q4
14 quarters
WMGI
17
DELISTED
Wright Medical Group Inc
WMGI
$70.7M 2%
2,372,157
-501,943
-17% -$15.3M
2018 Q3
3 quarters
XNCR icon
18
Xencor
XNCR
$1.78B
$66M 1.87%
1,612,798
-1,423,805
-47% -$46.8M
2016 Q4
10 quarters
SRPT icon
19
Sarepta Therapeutics
SRPT
$1.77B
$62.6M 1.77%
+412,000
New +$50.1M
2019 Q2
0 quarters
ELV icon
20
Elevance Health
ELV
$92B
$51.8M 1.47%
183,500
+6,800
+4% +$1.86M
2018 Q2
4 quarters
CELG
21
DELISTED
Celgene Corp
CELG
$51.5M 1.46%
557,000
+21,300
+4% +$2.02M
2019 Q1
1 quarter
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$51.5M 1.46%
3,462,300
-1,101,629
-24% -$19.9M
2018 Q2
4 quarters
DCPH icon
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$50.1M 1.42%
2,223,376
+594,723
+37% +$13.9M
2017 Q3
7 quarters
SRRK icon
24
Scholar Rock
SRRK
$4.86B
$46.3M 1.31%
2,920,389
+869,300
+42% +$16.1M
2018 Q2
4 quarters
KRYS icon
25
Krystal Biotech
KRYS
$9.73B
$43.5M 1.23%
1,080,300
+755,800
+233% +$24.7M
2018 Q4
2 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2019 Portfolio in Review

As of Q2 2019, Redmile Group held 99 positions worth $3.53B, up 3.4% from $3.42B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group's Q2 2019 filing shows 17 new, 28 increased, 21 reduced and 18 closed positions. Its largest new stake was Sarepta Therapeutics: 412,000 shares worth $62.6M. The largest sale was InflaRx, an estimated $82.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Miscellaneous and Financials.

  • Redmile Group's largest Q2 2019 buy was Sarepta Therapeutics: 412,000 shares worth $62.6M.
  • Redmile Group added most to Tricida, Inc. Common Stock in Q2 2019, an estimated $51.2M increase.
  • Redmile Group's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $62.3M.
  • Redmile Group fully exited InflaRx in Q2 2019, selling an estimated $82.5M.
  • Redmile Group's ten largest holdings make up 48% of its $3.53B portfolio in Q2 2019.
  • Redmile Group opened 17 new positions and closed 18 in Q2 2019.
  • Redmile Group's portfolio value rose 3.4% quarter-over-quarter to $3.53B.

Based on Redmile Group's 13F filing for Q2 2019, filed 14 Aug 2019.